Tanaka Hajime, Gunasekaran Sivagami, Saleh Dina Mourad, Alexander William T, Alexander David B, Ohara Hirotaka, Tsuda Hiroyuki
Department of Community-Based Medical Education, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Nanotoxicology Project, Nagoya City University, Nagoya, Japan.
Biochem Cell Biol. 2021 Feb;99(1):159-165. doi: 10.1139/bcb-2020-0087. Epub 2020 Sep 9.
Patients with ulcerative colitis or colonic Crohn's disease have a significantly increased risk of developing colorectal cancer. Bovine lactoferrin (bLF) reportedly inhibited the development of colon cancer in rats and mice, and in a placebo controlled trial, ingestion of bLF inhibited the growth of intestinal polyps. In addition, in a case study, a patient with Crohn's disease was reported to have remained in remission for over 7 years while ingesting 1 g of bLF daily. Thus, bLF has an inhibitory effect on colon carcinogenesis, and it may also promote remission of Crohn's disease. The purpose of this study was to investigate the effects of bLF in a mouse model of colorectal cancer related to irritable bowel disease (IBD). The mice were divided into 4 groups: () no treatment; () treated with bLF only; () treated with azoxymethane plus dextran sulfate sodium (AOM + DSS); and () treated with AOM + DSS + bLF. AOM was used to initiate intestinal cancer, and DSS was used to induce IBD-like inflammation in the intestine of the C57BL/6 mice. At the end of the study, the mice treated with AOM + DSS + bLF had a better fecal score, fewer lesions in the colon, and less weight loss than the mice treated with AOM + DSS without bLF. However, there were no statistically significant differences between the two groups with respect to tumor burden.
溃疡性结肠炎或结肠克罗恩病患者患结直肠癌的风险显著增加。据报道，牛乳铁蛋白（bLF）可抑制大鼠和小鼠结肠癌的发展，并且在一项安慰剂对照试验中，摄入bLF可抑制肠息肉的生长。此外，在一项病例研究中，据报道一名克罗恩病患者在每日摄入1克bLF的情况下病情缓解超过7年。因此，bLF对结肠癌发生具有抑制作用，并且它可能还促进克罗恩病的缓解。本研究的目的是在与肠易激病（IBD）相关的结直肠癌小鼠模型中研究bLF的作用。将小鼠分为4组：（）不治疗；（）仅用bLF治疗；（）用氧化偶氮甲烷加葡聚糖硫酸钠（AOM + DSS）治疗；以及（）用AOM + DSS + bLF治疗。使用AOM引发肠道癌症，并使用DSS在C57BL/6小鼠的肠道中诱导IBD样炎症。在研究结束时，与未使用bLF的AOM + DSS治疗组小鼠相比，使用AOM + DSS + bLF治疗的小鼠粪便评分更好、结肠病变更少且体重减轻更少。然而，两组在肿瘤负荷方面没有统计学上的显著差异。
